VivoSeq
Other

Treatment Outcome

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Treatment Outcome is an early-stage landscape with 0 programs across 4 companies. The most active players are Bayer, Pfizer, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalK

Kythera Biopharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed12 · 52%
Unknown status5 · 22%
Recruiting2 · 9%
No longer available1 · 4%
Withdrawn1 · 4%
Not yet recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

23 trials

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Recruiting·—·N/A·NCT07051850·174 enrolled
Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Recruiting·—·N/A·NCT07057765·40 enrolled
Real-life Treatment Outcomes of Ravulizumab in PNH
Active, not recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06633536·64 enrolled
Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
Not yet recruiting·VVersiti Blood Health·Phase 4·NCT07158606·15 enrolled
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
Completed·Bayer logoBayer·N/A·NCT00410306·1,493 enrolled
Treatment Outcome in Elderly Patients
Completed·UUniversity Hospital, Grenoble·Phase 3·NCT00700544·330 enrolled
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Completed·Pfizer logoPfizer·N/A·NCT04198571·317 enrolled
Treatment Outcome of Vascular Depression
Completed·UUniversity of Pennsylvania·N/A·NCT00045773·208 enrolled
ADHD Medication and Predictors of Treatment Outcome
Completed·KKarolinska Institutet·N/A·NCT02136147·632 enrolled
Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression
Completed·MMassachusetts General Hospital·Phase 4·NCT00157547·95 enrolled
Local Application of Hyaluronic Acid (HYADENT BG) With Free Soft Tissue Grafing Improves Treatment Outcomes.
Completed·JJordan University of Science and Technology·Phase 2/3·NCT04821804·24 enrolled
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
Completed·Bayer logoBayer·N/A·NCT03278262·2,312 enrolled
Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
Completed·MMayo Clinic·Phase 4·NCT03818191·288 enrolled
Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00881491·10 enrolled
Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
Completed·RRadboud University Medical Center·N/A·NCT01995981·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)